<DOC>
	<DOCNO>NCT00000886</DOCNO>
	<brief_summary>To evaluate safety HIV-1 gp120 C4-V3 hybrid polyvalent peptide immunogen ( C4-V3 peptide ) formulate mineral oil contain mannose mono-oleate ( IFA ) HIV-1 uninfected volunteer . To evaluate humoral cellular immune response C4-V3 peptide measure induction 1 following : neutralizing antibody HIV-1 MN RF , cross-neutralizing antibody primary isolates HIV-1 , HIV-1 antigen-specific lymphoproliferation , CD8+ CD4+ cytotoxic T lymphocyte ( CTL ) activity specific HIV-1 gp120 V3 peptides corresponding vaccine strain HIV-1 , induction HLA-B7 HLA-A2 restrict CD8+CTLs , induction HIV-specific DTH response . The test immunogen ( C4-V3 peptide ) construct 4 sequence HIV-1 V3 gp120 loop share approximately 80 % North American HIV-1 strain . Because critical role region play generate anti-HIV sequence , hypothesize test immunogen ( C4-V3 peptide ) capable induce broad range cross-reactive neutralizing antibody majority recipient .</brief_summary>
	<brief_title>A Phase I Safety Immunogenicity Trial HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed Mineral Oil Containing Mannose Mono-Oleate ( IFA )</brief_title>
	<detailed_description>The test immunogen ( C4-V3 peptide ) construct 4 sequence HIV-1 V3 gp120 loop share approximately 80 % North American HIV-1 strain . Because critical role region play generate anti-HIV sequence , hypothesize test immunogen ( C4-V3 peptide ) capable induce broad range cross-reactive neutralizing antibody majority recipient . Twenty-eight volunteer randomize receive two 0.5 ml injection C4-43 peptide IFA placebo ( IFA alone ) administer intramuscularly 0 , 1 , 6 , 12 month . At least 50 % volunteer ( 6 per Groups I II ; 2 , Group III ) must HLA-B7 phenotype .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Mineral Oil</mesh_term>
	<criteria>Inclusion Criteria Volunteers must : Negative ELISA HIV within 8 week immunization . Normal history physical examination . Normal chest xray within 4 week prior initial immunization . Lowrisk sexual behavior define AVEG . Exclusion Criteria Coexisting Condition : Volunteers follow condition exclude : Medical psychiatric condition precludes compliance protocol , include recent suicidal ideation present psychosis . Occupational responsibility preclude compliance protocol . Active syphilis ( serology document false positive due remote [ 6 month ] treat infection , volunteer eligible ) . Active tuberculosis ( volunteer positive purify protein derivative normal chest xray show evidence TB require isoniazid therapy eligible ) . Positivity hepatitis B surface antigen . Volunteers follow prior condition exclude : History immunodeficiency , chronic illness , malignancy , autoimmune disease . NOTE : Individuals history cancer exclude unless surgical excision follow sufficient observation period give reasonable assurance cure . History suicide attempt past psychosis . History anaphylaxis serious adverse reaction vaccine . History serious allergic reaction substance , require hospitalization emergent medical care ( e.g. , StevensJohnson syndrome , bronchospasm , hypotension ) . History lung disease . Prior Medication : Excluded : Live attenuate vaccine within 60 day study . NOTE : Medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal ) exclusionary , give least 2 week away HIV immunization . Experimental agent within 30 day prior study . HIV1 vaccine placebo , receive previous HIV vaccine trial . Immunosuppressive medication . Prior Treatment : Excluded : Receipt blood product immunoglobulin past 6 month . Risk Behavior : Excluded : Alcohol intake great equal equivalent 1 oz 100 proof per day ( 4 oz . glass wine 12 oz . beer per day ) . Identifiable higherrisk behavior HIV infection determine screening question design identify risk factor HIV infection ; specific exclusion include history injection drug use within last 12 month prior enrollment high immediaterisk sexual behavior define AVEG ( i.e. , meet criterion AVEG Risk Groups C D ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HIV Antibodies</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>Drug Carriers</keyword>
	<keyword>Hypersensitivity , Delayed</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>CD4-Positive T-Lymphocytes</keyword>
	<keyword>CD8-Positive T-Lymphocytes</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Neutralization Tests</keyword>
	<keyword>Mineral Oil</keyword>
	<keyword>Oleic Acids</keyword>
	<keyword>Mannose</keyword>
	<keyword>HLA-B7 Antigen</keyword>
	<keyword>HLA-A2 Antigen</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>